Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Layoffs follow at Nektar after IL-2 drug failure

by Jessica Marshall
April 30, 2022 | A version of this story appeared in Volume 100, Issue 15

 

Nektar Therapeutics says it will lay off 70% of its 700-plus employees. The news follows the April 14 announcement that Nektar and partner Bristol Myers Squibb were halting development of the interleukin-2 (IL-2) therapy bempegaldesleukin. The drug was intended to stimulate growth of T cells, which can attack cancer, but it failed in late-stage trials. Nektar, which focuses on immune modulation, says it will keep working on other drugs in its pipeline.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.